Cellinfinity BIO
Manufacturing partner uBriGene identifies Cellinfinity’s CIB-301 and CIB-350 as in vivo CAR-T programs for hematologic and solid tumors, supported by lentiviral vector manufacturing. The March 2026 announcement does not establish a registered clinical phase or human efficacy.
Corporate information
- Company entity
- Cellinfinity BIO
- Headquarters / principal office
- Public office in New Haven, Connecticut; NIH also lists San Francisco operationsOfficial contact address, not independently verified as a legal registered office. ↗
- Founded
- 2021 (holding entity) ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.cellinfinitybio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Manufacturing partner uBriGene identifies Cellinfinity’s CIB-301 and CIB-350 as in vivo CAR-T programs for hematologic and solid tumors, supported by lentiviral vector manufacturing. The March 2026 announcement does not establish a registered clinical phase or human efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Cellinfinity BIO — primary program / ownership disclosure
- NIH — Cellinfinity Bio company showcase
- Cellinfinity
- Founding / incorporation disclosure — scope stated in field